Genentech

 
 
 
Changes in bevacizumab (Avastin, Genentech, Inc.) package insert regarding: risk of ovarian failure, osteonecrosis of the jaw, risk of venous thromboembolic event (VTE) and bleeding in patients receiving anticoagulation therapy after first VTE event.
 
This is to inform you of changes made to the bevacizumab package insert on September 30, 2011. These changes include the following: